Health Services Utilization After Mandatory Switchover to Infliximab Biosimilars in British Columbia
British Columbia (BC) first province Implement a mandatory non-medical switch policy from infliximab (Remicade) to biosimilars in Canada. Phase 1 of the biosimilar program began on May 27, 2019, focusing …
Health Services Utilization After Mandatory Switchover to Infliximab Biosimilars in British Columbia Read More